Jim Cramer Shows Concerns That Eli Lilly “Might Be a Little Diluted”

Eli Lilly and Company (NYSE:LLY) is one of the stocks in Jim Cramer’s game plan for this week. Cramer highlighted that his Charitable Trust sold a small part of its stock holding at a substantial profit. He said:

“Thursday, we’re waiting for the numbers from a club name, Eli Lilly, with baited breath, frankly, because of the horrendous numbers from their only real GLP-1 competitor, Novo Nordisk. We don’t know if that’s happening because Lilly’s taking share from the poorly run Novo, or if companies are seeing a peak in these revolutionary weight loss drugs. My presumption is that it could be a little bit of both. I’m concerned that Lilly might be a little diluted because Novo cut prices on Wegovy pretty substantially. Now, we sold a little this week for the Charitable Trust, a huge gain. Give me a break.”

Jim Cramer Shows Concerns That Eli Lilly "Might Be a Little Diluted"

A laptop and a computer monitor display a detailed stock market technical analysis chart. Photo by Jakub Zerdzicki on Pexels

Eli Lilly (NYSE:LLY) develops and markets pharmaceuticals for conditions including diabetes, obesity, cancer, autoimmune disorders, and neurological diseases. The company’s portfolio includes treatments across endocrinology, oncology, immunology, and neuroscience.

While we acknowledge the risk and potential of LLY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than LLY and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.